0001104659-19-034791.txt : 20190611 0001104659-19-034791.hdr.sgml : 20190611 20190611163115 ACCESSION NUMBER: 0001104659-19-034791 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20190607 FILED AS OF DATE: 20190611 DATE AS OF CHANGE: 20190611 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Duncan Barbara Gayle CENTRAL INDEX KEY: 0001353128 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-12104 FILM NUMBER: 19891346 MAIL ADDRESS: STREET 1: C/O INTERCEPT PHARMACEUTICALS, INC. STREET 2: 18 DESBROSSES STREET CITY: NEW YORK STATE: NY ZIP: 10013 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: IMMUNOMEDICS INC CENTRAL INDEX KEY: 0000722830 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] IRS NUMBER: 611009366 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 300 AMERICAN RD CITY: MORRIS PLAINS STATE: NJ ZIP: 07950 BUSINESS PHONE: 9736058200 MAIL ADDRESS: STREET 1: 300 AMERICAN ROAD CITY: MORRIS PLAINS STATE: NJ ZIP: 07950 4 1 a4.xml 4 X0306 4 2019-06-07 0 0000722830 IMMUNOMEDICS INC IMMU 0001353128 Duncan Barbara Gayle 62 LAKESHORE DRIVE EASTCHESTER NY 10709 1 0 0 0 Common Stock, $0.01 par value per share 2019-06-07 4 A 0 9667 0 A 9667 D Stock Option (right to buy) 12.93 2019-06-07 4 A 0 17077 0 A 2020-06-07 2026-06-07 Common Stock, par value $0.01 per share 17077 17077 D Such grants of restricted stock units and stock options were made automatically pursuant to the Issuer's compensation policy for non-employee directors as of the date of the Issuer's 2019 annual meeting of stockholders, which occurred on June 7, 2019. Includes restricted stock units that represent a contingent right to receive one share of the Issuer's common stock. The restricted stock units shall vest on the first anniversary of the date of grant, subject to the Reporting Person's continued service as a director of the Issuer. The stock options vest on the first anniversary of the date of grant, subject to the Reporting Person's continued service as a director of the Issuer. /s/ Barbara Duncan 2019-06-11